New artificial heart valve could help patients too sick for surgery

NCT ID NCT07705594

Ongoing Disease control Sponsor: Jenscare Scientific Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial tests a new artificial valve, called LuX-Valve Plus, for people with severe tricuspid regurgitation (a leaky heart valve) who are not candidates for open-heart surgery. Participants are randomly assigned to receive either the valve implant plus standard medical therapy or standard therapy alone. The study measures whether the valve can reduce leak severity, improve symptoms, and avoid serious complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a transvenous artificial tricuspid valve system called LuX-Valve Plus
What this could lead to: If successful, this could offer a new treatment option for people with severe tricuspid regurgitation who are too high-risk for surgery.
What could go wrong: This is an early-stage trial with a small number of participants, so results may not apply to everyone. There are risks of serious complications like stroke, bleeding, or device-related problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRICUSPID REGURGITATION (TR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRICUSPID REGURGITATION (TR)

Contacts and locations

Show contact details

Locations

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.